- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05225064
Increasing COVID-19 Vaccine Uptake in Developing Countries (Bihar)
Visão geral do estudo
Status
Condições
Descrição detalhada
The goal of the study is to identify strategies that best promote and support COVID vaccine uptake in developing countries, we propose to test a range of scalable social and behavioural interventions. This could help policy makers design and employ interventions that are effective. This is especially valuable in resource constrained contexts where funds and institutional resources can be diverted towards interventions that have proven to work.
In Bihar the intervention will be village-level social mobilization involving community promotion, including in-person vaccine reinforcement, and household-level social mobilization. Some treatment villages will receive household- level interventions with varying intensity (different proportion of households will be visited). There will also an accompanying mask distribution campaign during household visits where the importance of mask-wearing as a complement to vaccine use will be explained.
This ClinicalTrials entry contains results only for the study in Bihar.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Bihar
-
Patna, Bihar, Índia, 800001
- Project Concern International
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Lives in study village
Exclusion Criteria:
- Does not live in study village
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Sem intervenção: Control
No vaccine or mask promotion, but access to vaccines increased to match access in intervention villages
|
|
|
Experimental: Village-level vaccine clinics with monetary, non-monetary, or no incentive
Village-level vaccine clinics with monetary, non-monetary, or no incentive.
Villages are cross-randomized to grocery coupon, food ration, no incentive, or grocery coupon to both community member and community health worker after the community member has received a vaccination.
|
Individuals will be provided with a guaranteed cash payment, entry into a cash lottery, or guaranteed gift of food if they are vaccinated
Vaccines are conducted at the household-level rather than the village-level
Village-level social mobilization campaign to be vaccinated
|
|
Experimental: Household-level vaccination with monetary or no incentive
Household-level vaccination with monetary incentive or no incentive.
Villages are cross-randomized to grocery coupon or no incentive upon receiving vaccination
|
Individuals will be provided with a guaranteed cash payment, entry into a cash lottery, or guaranteed gift of food if they are vaccinated
Vaccines are conducted at the household-level rather than the village-level
Village-level social mobilization campaign to be vaccinated
|
|
Experimental: Village-level vaccination without incentive, plus mask promotion
Individuals are encourage to attend village-level vaccine clinics but not given any incentive.
Mask distribution and reinforcement activities are conducted in villages at a similar time as vaccine promotion.
|
Vaccines are conducted at the household-level rather than the village-level
Village-level social mobilization campaign to be vaccinated
Individuals are given cloth masks
Individuals who are not wearing masks over their mouth and nose are stopped in public places and encouraged to wear a mask
|
|
Experimental: Village-level vaccination without incentive
Individuals are encourage to attend village-level vaccine clinics but not given any incentive.
|
Vaccines are conducted at the household-level rather than the village-level
Village-level social mobilization campaign to be vaccinated
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percent of individuals who receive the first, second, or third dose of covid vaccine
Prazo: up to 4 weeks (endline may vary depending on estimated uptake rates)
|
Prevalence of vaccination with difference doses
|
up to 4 weeks (endline may vary depending on estimated uptake rates)
|
Colaboradores e Investigadores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2000031541
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .